10X Genomics
TXG
$65.12
+1.96%
10x Genomics is a life science technology company that provides integrated instruments, consumables, and software for analyzing biological systems at high resolution and scale, primarily serving researchers in genomics and spatial biology. The company is a market leader in single-cell and spatial genomics, with its Chromium, Visium, and Xenium platforms widely adopted in academic and pharmaceutical research. The current investor narrative centers on a dramatic turnaround, as the stock has surged over 390% in the past year, driven by strong adoption of its spatial biology products and improving financial performance, though the company remains unprofitable on a trailing basis. Recent attention has focused on the company's ability to sustain growth momentum and achieve profitability, with analysts maintaining a bullish consensus.…
TXG
10X Genomics
$65.12
TXG 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on 10X Genomics's 12-month outlook, with a consensus price target around $49.54 and implied upside of -23.9% versus the current price.
Average Target
$49.54
0 analysts
Implied Upside
-23.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$40 - $65
Analyst target range
Analyst coverage is robust with 13 analysts, and the consensus recommendation is 'Buy' with a mean rating of 2.31 (where 1 is Strong Buy and 5 is Sell). The average price target is $49.54, which implies a downside of -23.9% from the current price of $65.12, suggesting that the stock has surged ahead of analyst expectations. The target range is $40.00 to $65.00, with the high target at the current price, indicating that even the most bullish analyst sees limited upside from here. The wide spread between the low and high targets (62.5% difference) reflects high uncertainty about the company's future growth and profitability, and recent ratings have been mixed, with some firms maintaining Neutral stances while others remain Overweight, suggesting a lack of consensus on the stock's fair value.
Drowning in data?
Find the real signal!
Bulls vs Bears: TXG Investment Factors
TXG presents a classic high-growth, high-risk investment case. The bull case is anchored by a 397% stock surge, expanding gross margins to 70.4%, narrowing losses, and a strong product franchise in spatial genomics. However, the bear case is equally compelling: the stock trades 23.9% above the average analyst target, revenue declined 2.6% YoY, and the forward PE of 320x prices in perfection. The most critical tension is whether the company can reignite revenue growth and achieve profitability, as the current valuation leaves no room for disappointment. Given the extreme overextension relative to analyst targets, the bear side currently has stronger evidence, but the company's strategic position could quickly shift the balance if growth accelerates.
Bullish
- Explosive 397% 1-Year Stock Rally: TXG has surged 397.1% over the past year, far outpacing the S&P 500's 20.5% gain, with relative strength of 376.6%. This reflects strong market conviction in the company's spatial biology growth story and improving fundamentals.
- Gross Margin Expansion to 70.4%: Q1 2026 gross margin reached 70.4%, up from 68.1% in Q1 2025, driven by a favorable product mix shift toward consumables, which now represent 86% of product revenue. This recurring revenue model enhances profitability potential.
- Narrowing Losses and Positive FCF: Net loss improved to -$13.5M in Q1 2026 from -$34.4M a year earlier, and trailing twelve-month free cash flow is positive at $122.2M. This demonstrates improving operational efficiency and financial sustainability.
- Undervalued on Price-to-Sales: At 3.17x PS, TXG trades well below its historical average and near the bottom of its 5-year range (6.9x-185.7x). Despite a 26.8% premium to the healthcare sector average of 2.5x, the growth potential may justify this.
Bearish
- Stock Trades 23.9% Above Average Target: At $65.12, TXG is 23.9% above the average analyst target of $49.54, and even the highest target of $65.00 is at the current price. This suggests the market has run ahead of fundamental expectations.
- Revenue Declined 2.6% YoY in Q1: Q1 2026 revenue of $150.8M fell 2.6% year-over-year, breaking a streak of sequential growth. This raises concerns about demand sustainability, especially as instrument revenue dropped significantly.
- Negative Operating Margin of -11.3%: Despite strong gross margins, operating margin was -11.3% in Q1 2026, reflecting heavy R&D ($56.8M) and SGA ($66.4M) spending. The company remains unprofitable on a GAAP basis.
- Extremely High Forward PE of 320x: The forward PE of 320.3x implies the market expects a dramatic earnings recovery, which is speculative given consensus EPS estimates of -$0.17 for the next fiscal year. This leaves little room for error.
TXG Technical Analysis
10x Genomics is in a powerful sustained uptrend, with the stock price at $65.12 as of August 21, 2026, representing a 397.1% increase over the past year. The current price is at 99.5% of its 52-week range (52-week low of $11.16, high of $65.47), indicating the stock is trading near its highs, which reflects strong momentum but also potential overextension. The stock has outperformed the S&P 500 dramatically, with relative strength of 376.6% over the past year, underscoring its leadership position in the current market environment.
Beta
2.04
2.04x market volatility
Max Drawdown
-28.0%
Largest decline past year
52-Week Range
$11-$65
Price range past year
Annual Return
+397.1%
Cumulative gain past year
| Period | TXG Return | S&P 500 |
|---|---|---|
| 1m | +38.4% | +3.6% |
| 3m | +175.0% | +2.7% |
| 6m | +244.9% | +11.4% |
| 1y | +397.1% | +18.7% |
| ytd | +291.8% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TXG Fundamental Analysis
Revenue in the most recent quarter (Q1 2026) was $150.8 million, a 2.6% decline year-over-year, breaking a streak of sequential growth seen in 2025. However, the company's product mix is shifting, with consumables revenue of $129.8 million representing 86% of total product and service revenue, while instruments revenue of $11.3 million declined, suggesting a transition to a recurring revenue model. The company's gross margin remains strong at 70.4% in Q1 2026, but operating margin was -11.3%, reflecting continued investment in R&D and sales. Net income was -$13.5 million in Q1 2026, a narrower loss compared to the -$34.4 million in Q1 2025, indicating improving profitability trajectory.
Quarterly Revenue
$150843000.0B
2026-03
Revenue YoY Growth
-2.6%
YoY Comparison
Gross Margin
70.4%
Latest Quarter
Free Cash Flow
$122180000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TXG Overvalued?
Given that 10x Genomics has negative trailing earnings (EPS of -$0.10 in Q1 2026), the price-to-sales (PS) ratio is the most appropriate valuation metric, and at 3.17x, it is significantly lower than the company's historical average, suggesting a potential value opportunity. The forward PE of 320.3x implies the market expects a dramatic earnings recovery, which is reflected in the consensus EPS estimate of -$0.17 for the next fiscal year. Compared to the healthcare sector average PS ratio of approximately 2.5x, 10x Genomics trades at a 26.8% premium, which may be justified by its superior growth prospects and market leadership in spatial genomics. Historically, the stock's PS ratio has ranged from 6.9x to 185.7x over the past five years, and the current 3.17x is near the bottom of that range, indicating that the market is pricing in a more mature growth profile.
PE
-46.6x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
439.6x
Enterprise Value Multiple
